Assistant Professor, Urology, University of Texas Medical School, San Antonio
Urology
Dr. Robert S. Svatek, MD
|
|
Give Review
Robert Svatek works in the field of Urology. He studied medicine at University of Texas Southwestern Medical School. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Robert Svatek has written publications. He has 95 publications published with PubMed. The lastest paper is: 'Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
- Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
- The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.
- Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial.
- Perioperative outcomes and hospital reimbursement by type of radical Prostatectomy: results from a privately insured patient population.
- Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy.
- Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
- Health Related Quality of Life From A Prospective Randomized Clinical Trial of Robotic Assisted Laparoscopic Versus Open Radical Cystectomy.
- Prospective External Validation of Model for Bladder Cancer Detection.
- Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.
- The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease.
- Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis.
- Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, c...
- Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis.
- Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: a systematic review.
- Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the Bladder.
- Comprehensive handbook for developing a Bladder cancer cystectomy database.
- Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Tri...
- Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.
- Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.
- Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy.
- Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.
- ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers.
- Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis.
- What is evaluation of Hematuria by primary care physicians: Use of electronic medical records to assess practice patterns with intermediate follow-up.
- Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy.
- Evaluation of Vitamin E and Selenium Supplementation for the Prevention of Bladder Cancer in SWOG Coordinated SELECT.
- Clinical nodal staging scores for Bladder cancer: a proposal for preoperative risk assessment.
- Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.
- Decision curve analysis assessing the clinical benefit of NMP22 in the detection of Bladder cancer: secondary analysis of a prospective trial.
- Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery.
- Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of Bladder.
- Prognostic risk stratification of pathological stage T3N0 Bladder cancer after radical cystectomy.
- Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive Bladder cancer.
- Cost utility of prostate Cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
- Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy.
- Prognostic risk stratification of pathological stage T2N0 Bladder cancer after radical cystectomy.
- A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with Bladder...
- Upper Tract urothelial carcinoma: Impact of time to surgery.
- The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary Bladder.
- Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
- pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the Bladder.
- High-risk patients with Hematuria are not evaluated according to guideline recommendations.
- Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.
- Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
- Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.
- Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.
- Association between lymph node density and disease specific survival in patients with penile Cancer.
- Cardiac history and risk of post-cystectomy cardiac complications.
- Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
- High risk populations and cystectomy outcomes.
- Pre-treatment biomarker levels improve the accuracy of post-Prostatectomy nomogram for prediction of biochemical recurrence.
- Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
- Is there a rationale for Bladder cancer screening?
- Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate Cancer diagnosis.
- Preoperative plasma endoglin levels predict biochemical progression after radical Prostatectomy.
- Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate Cancer.
- Cost-effectiveness of prostate Cancer chemoprevention: a quality of life-years analysis.
- Role of urinary cathepsin B and L in the detection of Bladder urothelial cell carcinoma.
- The influence of clinical and pathological stage discrepancy on Cancer specific survival in patients treated for renal cell carcinoma.
- Should we screen for Bladder cancer in a high-risk population?: A cost per life-year saved analysis.
- The cost of prostate Cancer chemoprevention: a decision analysis model.
- Economic impact of screening for Bladder cancer using Bladder tumor markers: a decision analysis.
- Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial Bladder cancer.
- Magnetic resonance imaging characteristics of Renal tumors after radiofrequency ablation.
- Critical analysis of Prostate-specific antigen doubling time calculation methodology.
- Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?
- International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.
- Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort.
- Urine-based biomarkers for the early detection and surveillance of non-muscle invasive Bladder cancer.
- Screening for Bladder cancer using urine-based tumor markers.
- Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens.
- Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a Renal tumours.
- Prognostic value of syndecan-1 expression in patients treated with radical Prostatectomy.
- Screening for Bladder cancer: a perspective.
- Application of novel hemostatic agent during laparoscopic partial nephrectomy.
- Normative values for the American Urological Association Symptom Index (AUA-7) and short form Urogenital Distress Inventory (UDI-6) in patients 65 and older presenting...
- Serum laboratory values following uncomplicated laparoscopic urological surgery.
- Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate Cancer.
- Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.
- Re: lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for Bladder cancer: analysis of pooled data fro...
- Novel therapeutics for patients with non-muscle-invasive Bladder cancer.
- Editorial comment on: Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-vo...
- Editorial comment on: Assessment of pathological prostate Cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
- Conservative management in selected patients with upper Tract urothelial carcinoma compares favourably with early radical surgery.
- Validation of the AJCC TNM substaging of pT2 Bladder cancer: deep muscle invasion is associated with significantly worse outcome.
- Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.
- Words of wisdom. Re: Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for Bladder cancer detection. Lotan Y, Shariat SF; N...
- Words of wisdom. Re: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric Cancer.
- Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in Bladder cancer.
- Management of metastatic urothelial Cancer: the role of surgery as an adjunct to chemotherapy.
- p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers.
- Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive Bladder cancer.
- Cost-effectiveness of Bladder cancer screening.
Schools
University of Texas At Galveston Medical Branch
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystotomy
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas Southwestern Medical School -
University of Texas Medical Branch
Hospital
-
University Health System -
South Texas Veterans Health Care System
Drug Facts
| NPI NUMBER | 1922216431 | |
| NPPES Provider LastName | SVATEK | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 782293931 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 306.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 40.0 | |
| Percent Opioid Claims | 13.07 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922216431 |
| Last Name Of The Provider | SVATEK |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Thomas H. Bartholomew, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen R. Kraus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos B. Bermejo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher Boniquit, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Fitzgerald, MD |